These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3108369)
1. Functional T cell deficits after bone marrow transplantation across minor histocompatibility barriers: effects of graft-vs-host disease on precursor frequency of reactive cells. Ferrara JL; Daley JP; Burakoff SJ; Miller RA J Immunol; 1987 Jun; 138(11):3598-603. PubMed ID: 3108369 [TBL] [Abstract][Full Text] [Related]
2. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. Thiele DL; Charley MR; Calomeni JA; Lipsky PE J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780 [TBL] [Abstract][Full Text] [Related]
3. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors. Schwartz E; Lapidot T; Gozes D; Singer TS; Reisner Y J Immunol; 1987 Jan; 138(2):460-5. PubMed ID: 3098843 [TBL] [Abstract][Full Text] [Related]
4. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. Brochu S; Baron C; Hétu F; Roy DC; Perreault C J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519 [TBL] [Abstract][Full Text] [Related]
5. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
6. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
7. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Krenger W; Snyder K; Smith S; Ferrara JL Transplantation; 1994 Dec; 58(11):1251-7. PubMed ID: 7992370 [TBL] [Abstract][Full Text] [Related]
8. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM; Waller EK Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [TBL] [Abstract][Full Text] [Related]
9. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. Hamilton BL; Bevan MJ; Parkman R J Immunol; 1981 Feb; 126(2):621-5. PubMed ID: 6450246 [TBL] [Abstract][Full Text] [Related]
10. Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction. Iwasaki T; Fujiwara H; Iwasaki T; Shearer GM J Immunol; 1986 Nov; 137(10):3100-8. PubMed ID: 2945856 [TBL] [Abstract][Full Text] [Related]
11. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644 [TBL] [Abstract][Full Text] [Related]
12. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. Holländer GA; Widmer B; Burakoff SJ J Immunol; 1994 Feb; 152(4):1609-17. PubMed ID: 7907102 [TBL] [Abstract][Full Text] [Related]
13. Measurement of recipient-specific alloreactivity: is GVHD predictable? Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251 [TBL] [Abstract][Full Text] [Related]
14. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [TBL] [Abstract][Full Text] [Related]
15. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Drobyski WR; Majewski D; Hanson G Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102 [TBL] [Abstract][Full Text] [Related]
16. Thymic and extrathymic differentiation and expansion of T lymphocytes following bone marrow transplantation in irradiated recipients. Dulude G; Brochu S; Fontaine P; Baron C; Gyger M; Roy DC; Perreault C Exp Hematol; 1997 Aug; 25(9):992-1004. PubMed ID: 9257813 [TBL] [Abstract][Full Text] [Related]
17. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. Wall DA; Hamberg SD; Reynolds DS; Burakoff SJ; Abbas AK; Ferrara JL J Immunol; 1988 May; 140(9):2970-6. PubMed ID: 3129505 [TBL] [Abstract][Full Text] [Related]
18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Johnson BD; Becker EE; Truitt RL Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958 [TBL] [Abstract][Full Text] [Related]
19. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. Hamilton BL J Immunol; 1987 Oct; 139(8):2511-5. PubMed ID: 3498761 [TBL] [Abstract][Full Text] [Related]
20. A two-phase pathogenesis of graft-versus-host disease in mice. van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]